HLB제넥스

187420KOSDAQ

65.5 / 100

Reference Date: 2026-10-23

Financial Score30.0 / 40

News Sentiment12.5 / 25

Momentum13.0 / 20

Disclosure10.0 / 15

AI Analysis: PER is significantly undervalued vs. peers but ROE is below the industry average. Surged 21.8% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

HLB제넥스 is a biotech company founded in 2000, specializing in the development and production of customized enzymes and bio-healthcare materials using core technologies like microbial display and recombinant protein secretion. Its main business areas include industrial specialty enzymes, bio-healthcare materials, and microbiome-enzyme products, with key offerings such as eco-friendly catalase, lactase for GOS production, and nattokinase for cardiovascular health. The company is also advancing its pipeline drug GF103, an oral treatment for wet age-related macular degeneration, currently preparing for Phase I clinical trials.

Number of Employees

82people

Average Salary

57.5M KRW

Score Calculation Basis

Detailed Financial Score

PER

2.86Industry Average 15.008.0Point

Half of industry avg (excellent)

PBR

1.32Industry Average 1.202.5Point

Higher than industry avg (caution)

ROE

55.20Industry Average 8.007.0Point

6.9x industry avg (excellent)

Debt Ratio

33.29Industry Average 100.006.5Point

Half of industry avg (excellent)

Trend 2023~20256.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲26.8% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲122.2% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -4.4% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position5.0Point

52w mid range (43%)

Current 2,215Won52-week high 3,31052-week low 1,373

1-month return6.0Point

1m +21.77% (strong rise)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0

Neutral주식등의대량보유상황보고서(일반)2026-10-15
Neutral기업설명회(IR)개최2026-10-12